ATE174629T1 - Herstellung von proteinen mittels protein 7b2 - Google Patents
Herstellung von proteinen mittels protein 7b2Info
- Publication number
- ATE174629T1 ATE174629T1 AT92923809T AT92923809T ATE174629T1 AT E174629 T1 ATE174629 T1 AT E174629T1 AT 92923809 T AT92923809 T AT 92923809T AT 92923809 T AT92923809 T AT 92923809T AT E174629 T1 ATE174629 T1 AT E174629T1
- Authority
- AT
- Austria
- Prior art keywords
- protein
- pct
- expressing
- vivo
- sec
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 5
- 102000004169 proteins and genes Human genes 0.000 title abstract 5
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 238000000338 in vitro Methods 0.000 abstract 2
- 238000001727 in vivo Methods 0.000 abstract 2
- 108010006519 Molecular Chaperones Proteins 0.000 abstract 1
- 238000004220 aggregation Methods 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 238000010353 genetic engineering Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000003248 secreting effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4722—G-proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL9102009A NL9102009A (nl) | 1991-11-29 | 1991-11-29 | Produktie van bioactieve peptiden met recombinante cellen. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE174629T1 true ATE174629T1 (de) | 1999-01-15 |
Family
ID=19859984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT92923809T ATE174629T1 (de) | 1991-11-29 | 1992-11-27 | Herstellung von proteinen mittels protein 7b2 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US5708140A (de) |
| EP (1) | EP0614490B1 (de) |
| JP (1) | JPH07501448A (de) |
| AT (1) | ATE174629T1 (de) |
| AU (1) | AU675919B2 (de) |
| CA (1) | CA2123567A1 (de) |
| DE (1) | DE69227921D1 (de) |
| FI (1) | FI942442A (de) |
| HU (1) | HUT67739A (de) |
| NL (1) | NL9102009A (de) |
| WO (1) | WO1993011248A1 (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993025681A1 (en) * | 1992-06-11 | 1993-12-23 | New York University | A cytoplasmic chaperonin and methods of making and using it |
| US5474914A (en) * | 1992-07-29 | 1995-12-12 | Chiron Corporation | Method of producing secreted CMV glycoprotein H |
| DE69329202T2 (de) * | 1992-10-02 | 2001-03-29 | Research Corp. Technologies, Inc. | Methoden der erhöhung der sekretion von überexpremierten proteinen |
| GB9223816D0 (en) | 1992-11-13 | 1993-01-06 | Medical Res Council | Heat shock proteins and the treatment of tumours |
| US5688651A (en) * | 1994-12-16 | 1997-11-18 | Ramot University Authority For Applied Research And Development Ltd. | Prevention of protein aggregation |
| JPH09173078A (ja) * | 1995-09-14 | 1997-07-08 | Tadayuki Imanaka | 分子シャペロンを用いる蛋白質の製造方法 |
| US6294661B1 (en) * | 1996-05-14 | 2001-09-25 | Smithkline Beecham Corporation | Compounds |
| EP1187920A2 (de) | 1999-06-09 | 2002-03-20 | Arch Development Corporation | Rekombinante prionänhliche gene, proteine, materialien und verfahren davon |
| JP2003531622A (ja) * | 2000-05-03 | 2003-10-28 | エクスプレッシブ コンストラクツ，インコーポレイテッド | 組み換えタンパク質安定性および可溶性を改善する方法 |
| JP4528460B2 (ja) * | 2000-06-30 | 2010-08-18 | 株式会社東芝 | 半導体素子 |
| US20040138116A1 (en) * | 2002-08-30 | 2004-07-15 | Vincent Geenen | Tolerogenic approach for type 1 diabetes |
| EP1624886A2 (de) * | 2003-05-12 | 2006-02-15 | Expressive Constructs, Inc. | Verfahren zur erhöhung der zell- und gewebevariabilität |
| US20050261475A1 (en) * | 2004-02-13 | 2005-11-24 | Harvard Medical School | Solid-phase capture-release-tag methods for phosphoproteomic analyses |
| FR3008713B1 (fr) * | 2013-07-18 | 2016-11-25 | Commissariat Energie Atomique | Procede d'extraction et de purification d'acides nucleiques et tampons mis en œuvre |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8702590A (nl) * | 1987-10-30 | 1989-05-16 | Stichting Katholieke Univ | Eiwit 7b2 alsmede recombinant dna en cdna, mrna, en antilichamen voor 7b2 en werkwijze voor het detecteren van 7b2. |
| CA1340740C (en) * | 1987-12-08 | 1999-09-14 | Eileen R. Mulvihill | Co-expression in eukaryotic cells |
-
1991
- 1991-11-29 NL NL9102009A patent/NL9102009A/nl not_active Application Discontinuation
-
1992
- 1992-11-27 CA CA002123567A patent/CA2123567A1/en not_active Abandoned
- 1992-11-27 AU AU29461/92A patent/AU675919B2/en not_active Ceased
- 1992-11-27 US US08/244,492 patent/US5708140A/en not_active Expired - Fee Related
- 1992-11-27 EP EP92923809A patent/EP0614490B1/de not_active Expired - Lifetime
- 1992-11-27 HU HU9401604A patent/HUT67739A/hu unknown
- 1992-11-27 WO PCT/EP1992/002740 patent/WO1993011248A1/en active IP Right Grant
- 1992-11-27 JP JP5509807A patent/JPH07501448A/ja active Pending
- 1992-11-27 AT AT92923809T patent/ATE174629T1/de not_active IP Right Cessation
- 1992-11-27 DE DE69227921T patent/DE69227921D1/de not_active Expired - Lifetime
-
1994
- 1994-05-25 FI FI942442A patent/FI942442A/fi unknown
-
1996
- 1996-09-09 US US08/709,915 patent/US5804417A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2123567A1 (en) | 1993-06-10 |
| WO1993011248A1 (en) | 1993-06-10 |
| HU9401604D0 (en) | 1994-09-28 |
| NL9102009A (nl) | 1993-06-16 |
| AU675919B2 (en) | 1997-02-27 |
| EP0614490B1 (de) | 1998-12-16 |
| FI942442A0 (fi) | 1994-05-25 |
| US5804417A (en) | 1998-09-08 |
| EP0614490A1 (de) | 1994-09-14 |
| US5708140A (en) | 1998-01-13 |
| FI942442A (fi) | 1994-07-25 |
| DE69227921D1 (de) | 1999-01-28 |
| JPH07501448A (ja) | 1995-02-16 |
| HUT67739A (en) | 1995-04-28 |
| AU2946192A (en) | 1993-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE174629T1 (de) | Herstellung von proteinen mittels protein 7b2 | |
| DE69434447D1 (de) | Für die gentherapie verwendbare plasmide | |
| DE69323879D1 (de) | Herstellung von rekombinanten, menschlichem lactoferrin | |
| DE69435096D1 (de) | Zusammensetzung zur in vivo erzeugung von therapeutischen produkten | |
| ATE358176T1 (de) | Menschliche dnase | |
| BR0109494A (pt) | Produção de fatores recombinantes de coagulação do sangue em linhas celulares humanas | |
| DE69018920D1 (de) | Verwendung von dns-fragmenten, die ein signalpeptid kodieren zur sekretion von reifen proteinen in rekombinanten hefen, expressions-kassetten, transformierte hefen und verfahren zur herstellung dieser proteine. | |
| NL189092C (nl) | Hybride menselijke leukocytinterferons, dubbelstrengs dna dat hiervoor codeert, expressievector, transformant micro-organisme, werkwijzen ter bereiding daarvan en farmaceutisch preparaat. | |
| DE69123361D1 (de) | Verwendung von interleukin-4 zur behandlung der festen tumoren | |
| ATE207758T1 (de) | Verwendung von igf-1 | |
| ATE246247T1 (de) | Varianten des humanen rekombinanten interferon- gamma (rhu-ifn-gamma) mit erhöhter thermischer stabilität | |
| ATE107168T1 (de) | Verwendung von gepiron zur herstellung eines pharmazeutischen präparats zur behandlung atypischer depression. | |
| ATE175237T1 (de) | Polypeptide beteiligt an der kobalamin- und/oder kobamid-biosynthese, für diese kodierende dns- sequencen, und ihre herstellung und vewendung. | |
| AU669149B2 (en) | Expression signal-peptide-free staphylokinases | |
| DE69333962D1 (de) | Modifizierte zellen auf der basis des betain-katabolismus, herstellung und verwendung insbesondere zur herstellung von metaboliten oder enzymen | |
| DE69529750D1 (de) | Verbesserungen in der herstellung von proteinen in wirtszellen | |
| ATE45675T1 (de) | Verwendung von interferon gamma (ifn-gamma) zur herstellung von praeparationen zur behandlung rheumatischer erkrankungen. | |
| DE69728654D1 (de) | Verwendung von il-7 zur behandlung von autoimmunkrankheiten, insbesondere insulinabhängigem diabetes mellitus | |
| AU637589B2 (en) | Ancrod proteins, their production and use | |
| DE69916829D1 (de) | Genetisch veränderte fibroblasten und ihre verwendung | |
| DE69434072D1 (de) | Regulierende nukleinsaeuresequenzen und verwendungen | |
| SE9300509D0 (sv) | Peg treatment | |
| ATE124722T1 (de) | Für das plazentaprotein 9 (pp9) kodierende cdna, ihre isolierung und verwendung. | |
| EP0374909A3 (de) | Für das Plazentaprotein 11 (PP11) kodierende cDNA, ihre Isolierung und Verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |